A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is
Over the last decade the non-small cell lung cancer therapeutics landscape has been dominated by the increasing focus on identification and validation of molecular targets as well as identification of the best candidate agents to address these targets. Among the notable successes has been the approval of erlotinib, gefitinib and afatinib for the EGF receptor (EGFR) mutation and more recently crizotinib for anaplastic lymphoma kinase (ALK) gene rearrangement. Despite the excellent efficacy ofdoi:10.1158/1078-0432.ccr-14-1291 pmid:25564153 fatcat:mmdmpxen6jc6laoat4v4sys6vu